Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score^® Test from a US Societal Perspective

References

• Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: Updated recommendations of the international society of geriatric oncology (siog) and European society of breast cancer specialists (EUSOMA). Lancet Oncol. 2012;13(4):e148–e160. doi:10.1016/S1470-2045(11)70383-7
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Early and locally advanced breast cancer: Diagnosis and management.; 2018.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Guidelines: Breast Cancer, Version 4.2022; 2022.
   Google Scholar
• Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–3734. doi:10.1200/JCO.2005.04.7985
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65. doi:10.1016/S1470-2045(09)70314-6
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121. doi:10.1056/NEJMoa1804710
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–2347. doi:10.1056/NEJMOA2108873/SUPPL_FILE/NEJMOA2108873_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating tumor characteristics to maximize 21-gene assay utility: a cost-effectiveness analysis. J Natl Compr Cancer Netw. 2019;17(1):39–46. doi:10.6004/JNCCN.2018.7077
   PubMed Web of Science ®Google Scholar
• Kunst NR, Alarid-Escudero F, Paltiel AD, Wang SY. A value of information analysis of research on the 21-gene assay for breast cancer management. Value Heal. 2019;22(10):1102–1110. doi:10.1016/J.JVAL.2019.05.004/ATTACHMENT/C9092182-FB72-4552-BFB0-5A6BE5797ECC/MMC1.PDF
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Giordano SH, Niu J, Chavez-MacGregor M, et al. Estimating regimen-specific costs of chemotherapy for breast cancer: observational cohort study. Cancer. 2016;122(22):3447–3455. doi:10.1002/CNCR.30274
   PubMed Web of Science ®Google Scholar
• Bradley CJ, Neumark D, Bednarek HL, Schenk M. Short-term effects of breast cancer on labor market attachment: results from a longitudinal study. J Health Econ. 2005;24(1):137–160. doi:10.1016/J.JHEALECO.2004.07.003
   PubMed Web of Science ®Google Scholar
• Meadows ES, Johnston SS, Cao Z, et al. Illness-associated productivity costs among women with employer-sponsored insurance and newly diagnosed breast cancer. J Occup Environ Med. 2010;52(4):415–420. doi:10.1097/JOM.0B013E3181D65DB7
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. ICER’s Reference Case for Economic Evaluations: Principles and Rationale; 2020.
   Google Scholar
• Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395–2405. doi:10.1056/NEJMOA1904819
   PubMed Web of Science ®Google Scholar
• Geyer CE, Tang G, Mamounas EP, et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. Npj Breast Cancer. 2018;4(1). doi:10.1038/s41523-018-0090-6
   PubMed Web of Science ®Google Scholar
• Kalinsky K Predicting chemotherapy benefit in node-positive breast cancer with the 21-gene test: the oncotype dx breast recurrence score® Test. In: San Antonio Breast Cancer Conference; 2021.
   Google Scholar
• National Institute for Health and Care Excellence. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer; 2018.
   Google Scholar
• Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine Therapy—MONARCH 2: A randomized clinical trial. JAMA Oncol. 2020;6(1):116. doi:10.1001/JAMAONCOL.2019.4782
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Liposomal Cytarabine–Daunorubicin for Untreated Acute Myeloid Leukaemia.; 2018.
   Google Scholar
• Clinical Laboratory Fee Schedule Files | CMS. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files. Accessed June 21, 2022.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Guidelines: Breast Cancer, Version 2.2021; 2021.
   Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):1–8. doi:10.1186/s12916-021-02204-0
   PubMed Web of Science ®Google Scholar
• Choi IS, Jung J, Kim BH, et al. The 21-gene recurrence score assay and prediction of chemotherapy benefit: A propensity score-matched analysis of the SEER database. Cancers. 2020;12(7):1829. doi:10.3390/cancers12071829
   PubMed Web of Science ®Google Scholar
• Roberts MC, Miller DP, Shak S, Petkov VI. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Canc Res Treat. 2017;163(2):303–310. doi:10.1007/s10549-017-4162-3
   PubMed Web of Science ®Google Scholar
• Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with medicare claims. Med Care. 2016;54(9):e55–e64. doi:10.1097/MLR.0000000000000073
   PubMed Web of Science ®Google Scholar
• Albain KS, Gray RJ, Makower DF, et al. Race, ethnicity, and clinical outcomes in hormone receptor-Positive, HER2-Negative, node-negative breast cancer in the randomized tAILORx trial. J Natl Cancer Inst. 2021;113(4):390–399. doi:10.1093/JNCI/DJAA148
   PubMedGoogle Scholar
• Abdou Y, Barlow WE, Gralow JR, et al. Abstract GS1-01: race and clinical outcomes in the RxPONDER Trial (SWOG S1007). Cancer Res. 2023;83(5_Supplement):GS1–01. doi:10.1158/1538-7445.SABCS22-GS1-01
   Web of Science ®Google Scholar
• Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness analyses of the 21-Gene assay in breast cancer: systematic review and critical appraisal. J Clin Oncol. 2018;36(16):1619–1627. doi:10.1200/JCO.2017.76.5941
   PubMed Web of Science ®Google Scholar
• Berdunov V, Millen S, Paramore A, et al. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer. J Medl Eco. 2022;25(1):591–604. doi:10.1080/13696998.2022.2066399
   PubMed Web of Science ®Google Scholar
• Berdunov V, Millen S, Paramore A, et al. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer. Clin Outcomes Res CEOR. 2022;14:619. doi:10.2147/CEOR.S360049
   PubMed Web of Science ®Google Scholar